Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics' stock price has been impacted by several key events in the past six months. In May 2026, the stock surged after positive topline results from the REVEAL-2 Phase 3 clinical trial for elegrobart and the announcement of upsized public offerings totaling $350 million. In March 2026, the company's stock experienced a significant drop despite positive results from the REVEAL-1 Phase 3 trial for elegrobart. The stock has experienced volatility, partly influenced by Amgen's positive Phase 3 data for subcutaneous Tepezza.

There is no specific information available regarding demand seasonality for Viridian Therapeutics, Inc.'s products or services. Demand is likely driven by disease prevalence and treatment efficacy rather than seasonal factors.

Viridian Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for serious and rare diseases, particularly autoimmune conditions like Thyroid Eye Disease (TED). The company operates within the Healthcare sector, specifically in the Biotechnology industry, with sub-industries including Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Drug Discovery, and Pharmaceuticals. The company's major product candidates include Veligrotug (VRDN-001), Elegrobart (VRDN-003), VRDN-006 and VRDN-008, and an anti-thyroid-stimulating hormone receptor (TSHR) candidate.

Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States, and also maintains offices in Colorado, US.

Viridian Therapeutics' brand reputation has been closely tied to its clinical trial progress and market perception of its pipeline. Analyst sentiment remains largely positive, with a consensus of "Strong Buy". The successful Phase 3 REVEAL-2 trial for elegrobart in May 2026 significantly boosted the company's stock and likely enhanced its reputation. Despite positive data from the REVEAL-1 trial in March 2026, the subsequent stock drop indicated market concerns about the drug's competitive positioning. The positive Phase 3 data for Amgen's subcutaneous Tepezza has intensified competition in the TED market.

Viridian Therapeutics, Inc. has a diverse ownership structure, predominantly held by institutional investors. Approximately 104.61% of the company's stock is held by institutional shareholders, 30.20% by Viridian Therapeutics insiders, and a smaller portion by retail investors. Major institutional owners include FMR LLC, BlackRock Inc., The Vanguard Group, Inc., Bellevue Asset Management AG, Fairmount Funds Management LLC, VR Adviser, LLC, State Street Corp, Price T Rowe Associates Inc /md/, Perceptive Advisors Llc and Deep Track Capital, LP. Logos Global Master Fund LP is noted as a significant individual shareholder.